AMAG Pharmaceuticals, Inc. (AMAG) Coverage Initiated at Piper Jaffray Companies

Stock analysts at Piper Jaffray Companies started coverage on shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a research report issued to clients and investors on Monday. The brokerage set a “neutral” rating and a $18.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 15.76% from the company’s current price.

AMAG has been the subject of a number of other research reports. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Tuesday, July 11th. ValuEngine upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. Morgan Stanley started coverage on AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective for the company. Deutsche Bank AG reiterated a “hold” rating and issued a $24.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company’s stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average target price of $26.92.

Shares of AMAG Pharmaceuticals (AMAG) opened at 15.55 on Monday. The firm’s market cap is $548.73 million. AMAG Pharmaceuticals has a 52-week low of $15.20 and a 52-week high of $36.83. The company has a 50-day moving average of $18.27 and a 200 day moving average of $18.90.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.45 earnings per share. On average, equities analysts expect that AMAG Pharmaceuticals will post ($1.38) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) Coverage Initiated at Piper Jaffray Companies” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/2982095/amag-pharmaceuticals-inc-amag-coverage-initiated-at-piper-jaffray-companies.html.

Several institutional investors have recently added to or reduced their stakes in AMAG. Karp Capital Management Corp purchased a new stake in shares of AMAG Pharmaceuticals during the first quarter valued at $232,000. Sei Investments Co. boosted its position in shares of AMAG Pharmaceuticals by 0.7% during the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares during the last quarter. Mason Street Advisors LLC boosted its position in shares of AMAG Pharmaceuticals by 7.4% during the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 554 shares during the last quarter. Arizona State Retirement System boosted its position in shares of AMAG Pharmaceuticals by 1.7% during the first quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company’s stock valued at $404,000 after buying an additional 300 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its position in shares of AMAG Pharmaceuticals by 101.1% during the first quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock valued at $396,000 after buying an additional 8,836 shares during the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.